GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $8.18.

GDRX has been the subject of several recent analyst reports. KeyCorp decreased their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Citigroup decreased their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Wells Fargo & Company dropped their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Mizuho began coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective for the company. Finally, Morgan Stanley lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th.

GoodRx Trading Down 4.1 %

Shares of NASDAQ:GDRX opened at $4.47 on Friday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $1.71 billion, a PE ratio of -149.00, a P/E/G ratio of 2.46 and a beta of 1.25. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26. The firm has a fifty day moving average price of $4.72 and a 200 day moving average price of $5.58.

Institutional Trading of GoodRx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of GoodRx by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock valued at $38,935,000 after buying an additional 460,753 shares during the period. Rubric Capital Management LP raised its holdings in GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after acquiring an additional 943,226 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock worth $9,264,000 after acquiring an additional 369,553 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of GoodRx during the third quarter valued at approximately $11,295,000. Finally, Clearbridge Investments LLC bought a new stake in shares of GoodRx during the fourth quarter valued at approximately $5,863,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.